Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) CEO Abraham Ceesay sold 8,210 shares of Rapport Therapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $45.61, for a total value of $374,458.10. Following the completion of the transaction, the chief executive officer directly owned 458,977 shares of the company’s stock, valued at approximately $20,933,940.97. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Abraham Ceesay also recently made the following trade(s):
- On Tuesday, August 25th, Abraham Ceesay sold 18,921 shares of Rapport Therapeutics stock. The shares were sold at an average price of $49.57, for a total transaction of $937,913.97.
- On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58.
- On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The stock was sold at an average price of $46.26, for a total transaction of $1,042,746.66.
- On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $42.11, for a total transaction of $93,063.10.
Rapport Therapeutics Stock Up 0.4%
Shares of RAPP opened at $43.62 on Friday. Rapport Therapeutics, Inc. has a twelve month low of $22.73 and a twelve month high of $52.93. The company has a market capitalization of $2.09 billion, a P/E ratio of -14.35 and a beta of 1.02. The firm has a 50 day moving average of $44.73 and a 200 day moving average of $38.11.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of RAPP. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Rapport Therapeutics by 86.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock valued at $99,000 after purchasing an additional 4,582 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC purchased a new position in shares of Rapport Therapeutics in the first quarter worth approximately $2,039,000. Rhumbline Advisers boosted its holdings in shares of Rapport Therapeutics by 40.1% in the first quarter. Rhumbline Advisers now owns 14,358 shares of the company’s stock worth $144,000 after buying an additional 4,109 shares during the last quarter. Geode Capital Management LLC grew its position in Rapport Therapeutics by 5.5% during the second quarter. Geode Capital Management LLC now owns 333,159 shares of the company’s stock valued at $3,789,000 after buying an additional 17,496 shares during the period. Finally, Creative Planning bought a new stake in Rapport Therapeutics during the second quarter valued at approximately $121,000.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on RAPP shares. HC Wainwright boosted their target price on Rapport Therapeutics from $40.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Truist Financial assumed coverage on shares of Rapport Therapeutics in a report on Monday, May 18th. They set a “buy” rating and a $56.00 price target on the stock. Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a report on Tuesday, June 2nd. Wall Street Zen cut shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, William Blair initiated coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 28th. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Rapport Therapeutics has an average rating of “Buy” and an average price target of $62.86.
Get Our Latest Report on Rapport Therapeutics
Rapport Therapeutics Company Profile
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
See Also
- Five stocks we like better than Rapport Therapeutics
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
